Phio Pharmaceuticals Corp. (PHIO)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.80
- As of
Kresmion compiles this page from PHIO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Phio Pharmaceuticals Corp. (PHIO): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-05.
See the full PHIO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PHIO on one page. Preview it with sample data, then open it live with a free account.
Preview the PHIO dossierActive events for PHIO
- medium13F: new position
CITADEL ADVISORS LLC new position in PHIO
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +124% to PHIO (2026Q1)
- mediumEarnings below estimates
Q2-2025: Missed consensus by 22.5% - EPS $-0.45 vs $-0.3672 estimate
- mediumEarnings above estimates
Q4-2025: Beat consensus by 27.0% - EPS $-0.253 vs $-0.3468 estimate
- mediumEarnings below estimates
Q1-2026: Missed consensus by 41.8% - EPS $-0.34 vs $-0.2397 estimate
FREE, NO ACCOUNT
Every event on PHIO, as it fires
New filings, 13F moves and cross asset events on PHIO land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
PHIO positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| CITADEL ADVISORS LLC FundCUSIP 71880W501 · 2026Q2 | $48K | 0.00% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 71880W501 · 2026Q2 | $22K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PHIO
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
Going concern statement
PHIO's 10-Q filed Nov 5, 2026 states:
These factors raise substantial doubt regarding the Company's ability to continue as a going concern.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on PHIO
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in PHIO on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on PHIO in the last 180 days.
Upstream: SEC EDGAR filings for PHIO
Kresmion, "Phio Pharmaceuticals Corp. (PHIO) institutional holdings and SEC filings", data as of 2026-11-05, https://kresmion.com/research/PHIO. Upstream data: SEC EDGAR filings for PHIO.
Link to this data (HTML):
<a href="https://kresmion.com/research/PHIO">Phio Pharmaceuticals Corp. (PHIO) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow PHIO on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to PHIO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.